Tonix Pharmaceuticals (NASDAQ:TNXP) posted its earnings results on Monday. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.18), Bloomberg Earnings reports.
Tonix Pharmaceuticals opened at $2.88 on Tuesday, MarketBeat.com reports. Tonix Pharmaceuticals has a twelve month low of $2.78 and a twelve month high of $2.79. The company has a market cap of $23.02 million, a price-to-earnings ratio of -0.99 and a beta of 2.84.
A number of equities analysts have weighed in on TNXP shares. Brookline Capital Management reaffirmed a “buy” rating on shares of Tonix Pharmaceuticals in a research report on Tuesday, May 1st. ValuEngine downgraded Tonix Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Monday, April 2nd. Finally, Brookline Cap M reaffirmed a “buy” rating on shares of Tonix Pharmaceuticals in a research report on Tuesday, May 1st. Seven research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus target price of $8.33.
Tonix Pharmaceuticals Company Profile
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population.
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.